Abstract： In recent years,the incidence rate of malignant tumors has been ever increased. As the persistent advancement of various therapeutic techniques, the therapeutic plans of cancer have been improved. Radiotherapy takes effect mainly by killing the topical tumor cells by radiation. During radiotherapy, the anti-tumor immune response can be induced or enhanced. Appropriate radiotherapy dose and segmentation model combined with certain immunotherapy plays a more and more significant role in the treatment of tumors. In this article, the underlying mechanisms of radiation-enhanced anti-tumor immune response and the current status and research prospects of radiotherapy combined with immunotherapy were reviewed.
Qiao Hui,Song Wengang,Wan Long et al. Mechanism and research progress on radiotherapy combined with immunotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(8): 634-637.
[1] Sharabi AB,Lim M,DeWeese TL. Radiation and checkpoint blockade immunotherapy:radiosensitisation and potential mechanisms of synergy[J]. Lancet Oncol,2015, 16(13):e498-509. DOI:10.1016/S1470-2045(15)00007-8. [2] De La Cruz-Merino L,Illescas-Vacas A,Grueso-Lopez A,et al. Radiation for awakening the dormant immune system,a promising challenge to be explored[J]. Front Immunol,2014,5(1):102. DOI:10.3389/fimmu.2014.00102. [3] Lumniczky K,Safrany G. The impact of radiation therapy on the antitumor immunity:Local effects and systemic consequences[J]. Cancer Lett,2015,356(1):114-125. DOI:10.1016/j.canlet.2013.08.024. [4] Marincola FM,Jaffee EM,Hicklin DJ,et al. Escape of human solid tumors from T-cell recognition:molecular mechanisms and functional significance[J]. Adv Immunol,2000,74(1):181-273. DOI:10.1016/S0065-2776(08)60911-6. [5] Zeng J,See AP,Phallen J,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J]. Int J Radiat Oncol Biol Phys,2013,86(2):343-349. DOI:10.1016/j.ijrobp.2012.12.025. [6] Zhang B,Bowerman NA,Salama JK,et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells[J]. J Exp Med,2007,204(1):49-55. DOI:10.1084/jem.20062056. [7] Kalbasi A,June CH,Haas N,et al. Radiation and immunotherapy:a synergistic combination[J]. J Clin Invest,2013,123(7):2756-2763. DOI:10.1172/JCI69219. [8] Suzuki Y,Mimura K,Yoshimoto Y,et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma[J]. Cancer Res,2012,72(16):3967-3976. DOI:10.1158/0008-5472. CAN-12-0851. [9] Ifeadi V,Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways[J/OL]. PLoS One,2012,7(2):e31762. DOI:10.1371/journal.pone.0031762. [10] Formenti SC,Demaria S. Radiation therapy to convert the tumor into an in situ vaccine[J]. Int J Radiat Oncol Biol Phys,2012,84(4):879-880. DOI:10.1016/j.ijrobp.2012.06.020. [11] Roses RE,Datta J,Czerniecki BJ. Radiation as immunomodulator:Implications for dendritic cell-based immunotherapy[J]. Radiat Res,2014,182(2):211-218. DOI:10.1667/RR13495.1. [12] 胥芸芸,洪梅,李桂香. 放疗对机体抗肿瘤免疫效应机制的影响[J]. 现代肿瘤医学,2016,24(24):4023-4025. Xu YY,Hong M,Li G. New progress on the effect of radiotherapy on the anti-tumor immune response[J]. Mode Oncol,2016,24(24):4023-4025. [13] Kim KW,Kim SH,Shin JG,et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity[J]. Int J Cancer,2004,109(5):685-690. DOI:10.1002/ijc.20036. [14] Persa E,Balogh A,Safrany G,et al. The effect of ionizing radiation on regulatory T cells in health and disease[J]. Cancer Lett,2015,368(2):252-261. DOI:10.1016/j.canlet.2015.03.003. [15] Deng L,Liang H,Burnette B,et al. Irradiation and anti-PDL1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest,2014,124(2):687-695. DOI:10.1172/JCI67313. [16] 王绿化,朱广迎. 肿瘤放射治疗学[M]. 北京:人民卫生出版社,2016. Wang LH,Zhu GY. Radiation oncology[M]. Beijing:People′s health press,2016. [17] 刘超. NSCLC立体定向放疗和常规分割放疗的免疫效应及相关临床分析[D].合肥:安徽医科大学,2017. Liu C. Immunological effects and related clinical analysis of NSCLC stereotactic radiotherapy and conventional segmented radiotherapy[D]. Hefei:Anhui medical university,2017. [18] Gupta A,Probst HC,Vuong V,et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation[J]. J Immunol,2012,189(2):558-566. DOI:10.4049/jimmunol.1200563. [19] Dovedi SJ,Melis MH,Wilkinson RW,et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma[J]. Blood,2013,121(2):251-259. DOI:10.1182/blood-2012-05-432393. [20] Dewan MZ,Galloway AE,Kawashima N,et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res,2009,15(17):5379-5388. DOI:10.1158/1078-0432. CCR-09-0265. [21] Hanna N. Consolidation pembrolizumab following chemoradiation in patients with inoperable/unresectable stage Ⅲ NSCLC[EB/OL][2018-06-10].https://clinicaltrials.gov/ct2/show/NCT02343952. [22] Garrett M,Wang TJC,Cheng SK. Combined versus sequential radiation and immunotherapy in advanced lung cancer[J]. Int J Radiat Oncol Biol Phys,2017,99(2):E455-E456. DOI:10.1016/j.ijrobp.2017.06.1694. [23] Srivastava A,Huang J. The impact of the timing of PD-1 inhibition on disease control for brain metastases treated with stereotactic radiosurgery[J]. Int J Radiat Oncol Biol Phys,2017,99(2):E111. DOI:10.1016/j.ijrobp.2017.06.859. [24] Khan H. Durvalumab and consolidation SBRT following chemoradiation for locally advanced stage Ⅲ non-small cell lung[EB/OL][2018-06-10].https://clinicaltrials.gov/ct2/show/NCT03589547. [25] European,thoracic,oncology,platform.nivolumab combination with standard first-line chemotherapy and radiotherapy in locally advanced stage ⅢA/B non-small cell lung carcinoma[EB/OL][2018-06-10].https://clinicaltrials.gov/ct2/show/NCT02434081. [26] Reynders K,Illidge T,Siva S,et al. The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J]. Cancer Treat Rev,2015,41(6):503-510. DOI:10.1016/j.ctrv.2015.03.011. [27] Dovedi SJ,Adlard AL,Lipowska-Bhalla G,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res,2014,74(19):5458-5468. DOI:10.1158/0008-5472. [28] Yuan Z,Fromm A,Ahmed KA,et al. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1 negative metastatic squamous cell carcinoma of the lung[J]. J Thorac Oncol,2017,12(9):e135-e136. DOI:10.1016/j.jtho.2017.04.029. [29] Dovedi SJ,Adlard AL,Ota Y,et al. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy[J]. Oncotarget,2016,7(13):17035-17046. DOI:10.18632/oncotarget.7928. [30] Oweida AJ,Calame D,Lennon S,et al. Radiotherapy sensitizes head and neck tumors to PD-L1 immune checkpoint blockade[J]. Int J Radiat Oncol Biol Phys,2017,99(2):S202. DOI:10.1016/j.ijrobp.2017.06.501. [31] Srivastava A,Huang J. The impact of the timing of PD-1 inhibition on disease control for brain metastases treated with stereotactic radiosurgery[J]. Int J Radiat Oncol Biol Phys,2017,99(2):E111. DOI:10.1016/j.ijrobp.2017.06.859. [32] Grass GD,Sahebjam S,Macaulay RJ,et al. A comparison of outcomes in recurrent high grade gliomas treated with hypofractionated stereotactic radiation therapy with or without programmed cell death protein 1(PD-1) blockade[J]. Int J Radiat Oncol Biol Phys,2017,99(2):S102. DOI:10.1016/j.ijrobp.2017.06.244. [33] Bristol-Myers S. Efficacy study of nivolumab compared to docetaxel in subjects previously treated with advanced or metastatic non-small cell lung cancer[EB/OL][2018-06-10].https://www.clinicaltrials.gov/ct2/show/NCT02613507. [34] Fried DV,Person O,Mavroidis P,et al. Immunotherapy alter the dose/volume/outcome relationship in the normal brain?[J]. Int J Radiat Oncol Biol Phys,2017,99(2):E72-E73. DOI:10.1016/j.ijrobp.2017.06.764. [35] Louvel G,Bahleda R,Ammari S,et al. Immunotherapy and pulmonary toxicities:can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?[J]. Eur Respir J,2018,51(1):1701737-1701740. DOI:10.1183/13993003.01737-2017. [36] Shibaki R,Akamatsu H,Fujimoto M,et al. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy[J]. Ann Oncol,2017,28(6):1404-1405. DOI:10.1093/annonc/mdx115. [37] Johnson DB,Balko JM,Compton ML,et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. New Engl J Med,2016,375(18):1749-1755. DOI:10.1056/NEJMoa1609214. [38] Hiniker SM,Reddy SA,Maecker HT,et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma[J]. Int J Radiat Oncol Biol Phys,2016,96(3):578-588. DOI:1016/j.ijrobp.2016.07.005. [39] Murphy B,Walker J,Bassale S,et al. Concurrent radiosurgery and immunotherapy is associated with improved intracranial tumor control in patients with metastatic melanoma[J]. Int J Radiat Oncol Biol Phys,2017,99(2):E523-E524. DOI:10.1016/j.ijrobp.2017.06.1857. [40] Arnett ALH,Kottschade L,Wilhite TJ,et al. Toxicity of concurrent and sequential PD-1 immune check point inhibitors with conventional and hypofractionated radiation therapy in patients with metastatic disease[J]. Int J Radiat Oncol Biol Phys,2017,2017,99(2):E749. DOI:10.1016/j.ijrobp.2017.06.2402.
2019, Vol. 28 
